Literature DB >> 31644784

Adalimumab and the Challenges for Biosimilars.

Walid F Gellad1,2, Chester B Good2,3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31644784     DOI： 10.1001/jama.2019.16275

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors.

Authors:  Alvaro San-Juan-Rodriguez; Vincent M Piro; Chester B Good; Walid F Gellad; Inmaculada Hernandez
Journal:  J Manag Care Spec Pharm       Date:  2021-01

2.  The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring.

Authors:  Meenu Wadhwa; Chris Bird; Eleanor Atkinson; Isabelle Cludts; Peter Rigsby
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.